Results of whole-brain radiotherapy for primary central nervous system lymphoma at Vietnam National Cancer Hospital
Main Article Content
Abstract
Primary central nervous system lymphoma (ΡСNЅL) is a subtype of non-Hodgkin lymphoma restricted to the brain, leptomeninges, spinal cord and eyes without systemic involvement. This rare disease has distinct clinical features, treatment strategies, and prognoses compared to other brain tumors. High-dose methods form the backbone of PCNSL treatment due to its ability to cross the blood-brain barrier and achieve high response rates. Whole-brain radiotherapy (WBRT) plays a role as consolidation after high- dose methotrexate or as salvage therapy for patients who cannot tolerate systemic therapy or in cases of disease progression or recurrence. This is a retrospective cross-sectional study on 21 PCNSL patients who underwent whole-brain radiotherapy at Vietnam National Cancer Hospital from June 2019 to September 2024 to evaluate the treatment outcomes in this patient cohort. The median progression-free survival for the salvage radiotherapy and consolidation radiotherapy groups was 13.9 months and 14.6 months, respectively. The median overall survival for the salvage radiotherapy and consolidation radiotherapy groups was 27.2 months and 20.2 months, respectively; the difference was not statistically significant (p = 0.868).
Article Details
Keywords
Whole-brain radiotherapy (WBRT), primary central nervous lymphoma (PCNSL), treatment outcomes
References
2. Camilleri-Broet S, Martin A, Moreau A, et al. Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d’etude des Leucenies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. Nov 1998;110(5):607-12. doi:10.1093/ajcp/110.5.607
3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, The Journal of the American Society of Hematology. 2016;127(20):2375-2390.
4. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9-17. doi:10.1016/0360-3016(92)90538-s
5. Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro- Oncology. The Lancet Oncology. 2015;16(7):e322-e332.
6. Calimeri T, Steffanoni S, Gagliardi F, et al. How we treat primary central nervous system lymphoma. ESMO open. 2021;6(4):100213.
7. DeAngelis LM. Whither whole brain radiotherapy for primary CNS lymphoma? Neuro- oncology. 2014;16(8):1032.
8. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. Journal of Clinical Oncology. 2006;24(36):5711-5715.
9. Thomas A, Houillier C, Antoni D, et al. Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective. Reports of Practical Oncology and Radiotherapy. 2023;28(2):271-285.
10. Hyung J, Hong JY, Kim S, et al. Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma. Blood research. 2019;54(4):285-288.
11. Kansara R, Shenkier TN, Connors JM, et al. Rituximab with high‐dose methotrexate in primary central nervous system lymphoma. American journal of hematology. 2015;90(12):1149- 1154.
12. Phạm Hải Yến, Nguyễn Ngọc Dũng, Nguyễn Thị Mai. Nghiên cứu đặc điểm lâm sàng, xét nghiệm và kết quả điều trị U lympho không Hodgkin tế bào B lớn nguyên phát thần kinh TW tại Viện Huyết học truyền máu TW. Tạp chí Y học Việt Nam. 2022;520.
13. Đỗ Huyền Nga, Nguyễn Thị Thu Hường, Nguyễn Thanh Tùng. Đặc điểm lâm sàng và cận lâm sàng của u lympho nguyên phát thần kinh trung ương. Tạp chí Y học Việt Nam. 2024;541(1).
14. Aki H, Uzunaslan D, Saygin C, et al. Primary central nervous system lymphoma in immunocompetent individuals: A single center experience. International journal of clinical and experimental pathology. 2013;6(6):1068.
15. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
16. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non- inferiority trial. The lancet oncology. 2010;11(11):1036-1047.
17. Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. Journal of Clinical Oncology. 2005;23(7):1507-1513.
18. Fisher B, Seiferheld W, Schultz C, et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. Journal of neuro-oncology. 2005;74:201-205.
19. Bessell E, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. Journal of Clinical Oncology. 2002;20(1):231-236.
20. Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Journal of Clinical Oncology. 2013;31(31):3971-3979.
21. Omuro AMP, DeAngelis LM, Karrison T, et al. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low- dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). American Society of Clinical Oncology; 2020.
22. Lesueur P, Damaj G, Hoang-Xuan K, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Advances. 2022;6(16):4807-4815.